These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10463666)

  • 1. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections.
    Yardley V; Croft SL
    Am J Trop Med Hyg; 1999 Aug; 61(2):193-7. PubMed ID: 10463666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
    Yardley V; Croft SL
    Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
    Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
    Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
    Clemons KV; Stevens DA
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1047-50. PubMed ID: 14982807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.
    Cencig S; Coltel N; Truyens C; Carlier Y
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1216. PubMed ID: 21738811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of Efficacy of Liposomal Amphotericin B Against Acute and Chronic
    Clemons KV; Sobel RA; Martinez M; Correa-Oliveira R; Stevens DA
    Am J Trop Med Hyg; 2017 Oct; 97(4):1141-1146. PubMed ID: 28820684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.
    Mullen AB; Baillie AJ; Carter KC
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2722-5. PubMed ID: 9756784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental Trypanosoma cruzi Infections.
    Rolón M; Serrano DR; Lalatsa A; de Pablo E; Torrado JJ; Ballesteros MP; Healy AM; Vega C; Coronel C; Bolás-Fernández F; Dea-Ayuela MA
    Mol Pharm; 2017 Apr; 14(4):1095-1106. PubMed ID: 28198632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
    Olmo F; Guardia JJ; Marin C; Messouri I; Rosales MJ; Urbanová K; Chayboun I; Chahboun R; Alvarez-Manzaneda EJ; Sánchez-Moreno M
    Eur J Med Chem; 2015 Jan; 89():683-90. PubMed ID: 25462275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo trypanocidal activity of some benzimidazole derivatives against two strains of Trypanosoma cruzi.
    Díaz-Chiguer DL; Márquez-Navarro A; Nogueda-Torres B; de la Luz León-Ávila G; Pérez-Villanueva J; Hernández-Campos A; Castillo R; Ambrosio JR; Nieto-Meneses R; Yépez-Mulia L; Hernández-Luis F
    Acta Trop; 2012 Apr; 122(1):108-12. PubMed ID: 22212465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
    Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
    Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in human phospholipid transfer protein activity following incubation of Fungizone compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma.
    Henderson RJ; Leon CG; Wasan KM
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1139-46. PubMed ID: 19381990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains.
    Cencig S; Coltel N; Truyens C; Carlier Y
    Int J Antimicrob Agents; 2012 Dec; 40(6):527-32. PubMed ID: 23063742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.
    Yardley V; Croft SL
    Antimicrob Agents Chemother; 1997 Apr; 41(4):752-6. PubMed ID: 9087483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ravuconazole self-emulsifying delivery system: in vitro activity against
    Spósito PÁ; Mazzeti AL; de Oliveira Faria C; Urbina JA; Pound-Lana G; Bahia MT; Mosqueira VF
    Int J Nanomedicine; 2017; 12():3785-3799. PubMed ID: 28553114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis.
    Clemons KV; Stevens DA
    Antimicrob Agents Chemother; 1998 Apr; 42(4):899-902. PubMed ID: 9559804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of lytic peptides against intracellular Trypanosoma cruzi amastigotes in vitro and parasitemias in mice.
    Barr SC; Rose D; Jaynes JM
    J Parasitol; 1995 Dec; 81(6):974-8. PubMed ID: 8544074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentamidine exerts in vitro and in vivo anti Trypanosoma cruzi activity and inhibits the polyamine transport in Trypanosoma cruzi.
    Díaz MV; Miranda MR; Campos-Estrada C; Reigada C; Maya JD; Pereira CA; López-Muñoz R
    Acta Trop; 2014 Jun; 134():1-9. PubMed ID: 24560964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
    Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
    Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.
    Mullen AB; Carter KC; Baillie AJ
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2089-92. PubMed ID: 9333030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.